SE506771C2 - Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna - Google Patents

Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna

Info

Publication number
SE506771C2
SE506771C2 SE9600434A SE9600434A SE506771C2 SE 506771 C2 SE506771 C2 SE 506771C2 SE 9600434 A SE9600434 A SE 9600434A SE 9600434 A SE9600434 A SE 9600434A SE 506771 C2 SE506771 C2 SE 506771C2
Authority
SE
Sweden
Prior art keywords
bacteriophage
ecacc
phage
bacterial
infections
Prior art date
Application number
SE9600434A
Other languages
English (en)
Swedish (sv)
Other versions
SE9600434D0 (sv
SE9600434L (sv
Inventor
Sven Maardh
Original Assignee
Gotpat 105 Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gotpat 105 Ab filed Critical Gotpat 105 Ab
Priority to SE9600434A priority Critical patent/SE506771C2/sv
Publication of SE9600434D0 publication Critical patent/SE9600434D0/xx
Priority to CA002244792A priority patent/CA2244792A1/en
Priority to ES97902815T priority patent/ES2221033T3/es
Priority to NZ331580A priority patent/NZ331580A/en
Priority to JP52844697A priority patent/JP4015195B2/ja
Priority to AU16817/97A priority patent/AU712767B2/en
Priority to KR10-1998-0705761A priority patent/KR100459638B1/ko
Priority to IL12564597A priority patent/IL125645A0/xx
Priority to DE69728975T priority patent/DE69728975T2/de
Priority to PCT/SE1997/000172 priority patent/WO1997029185A1/en
Priority to CN97192116A priority patent/CN1125174C/zh
Priority to RU98116471/13A priority patent/RU2215032C2/ru
Priority to HU9901242A priority patent/HUP9901242A3/hu
Priority to AT97902815T priority patent/ATE266091T1/de
Priority to EP97902815A priority patent/EP0889955B1/de
Publication of SE9600434L publication Critical patent/SE9600434L/xx
Publication of SE506771C2 publication Critical patent/SE506771C2/sv
Priority to NO19983456A priority patent/NO323359B1/no
Priority to IL125645A priority patent/IL125645A/en
Priority to US09/927,420 priority patent/US20020044922A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/121—Helicobacter (G); Campylobacter (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00—Bacteriophages
    • C12N2795/00011—Details
    • C12N2795/14011—Details ssDNA Bacteriophages
    • C12N2795/14111—Inoviridae
    • C12N2795/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE9600434A 1996-02-06 1996-02-06 Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna SE506771C2 (sv)

Priority Applications (18)

Application Number Priority Date Filing Date Title
SE9600434A SE506771C2 (sv) 1996-02-06 1996-02-06 Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna
EP97902815A EP0889955B1 (de) 1996-02-06 1997-02-05 Rekombinante phagen
DE69728975T DE69728975T2 (de) 1996-02-06 1997-02-05 Rekombinante phagen
CN97192116A CN1125174C (zh) 1996-02-06 1997-02-05 重组噬菌体
NZ331580A NZ331580A (en) 1996-02-06 1997-02-05 Recombinant phages
JP52844697A JP4015195B2 (ja) 1996-02-06 1997-02-05 組換えファージ
AU16817/97A AU712767B2 (en) 1996-02-06 1997-02-05 Recombinant phages
KR10-1998-0705761A KR100459638B1 (ko) 1996-02-06 1997-02-05 재조합파아지
IL12564597A IL125645A0 (en) 1996-02-06 1997-02-05 Recombinant phages
CA002244792A CA2244792A1 (en) 1996-02-06 1997-02-05 Recombinant phages
PCT/SE1997/000172 WO1997029185A1 (en) 1996-02-06 1997-02-05 Recombinant phages
ES97902815T ES2221033T3 (es) 1996-02-06 1997-02-05 Fagos recombinantes.
RU98116471/13A RU2215032C2 (ru) 1996-02-06 1997-02-05 Конструкция модифицированного нитевидного бактериофага для лечения или профилактики бактериальной инфекции, модифицированный бактериофаг м13, фармкомпозиция и способ лечения бактериальной инфекции, моноклональное антитело, гибридома (вариант)
HU9901242A HUP9901242A3 (en) 1996-02-06 1997-02-05 Recombinant phages
AT97902815T ATE266091T1 (de) 1996-02-06 1997-02-05 Rekombinante phagen
NO19983456A NO323359B1 (no) 1996-02-06 1998-07-27 Anvendelse av en modifisert bakteriofag til fremstilling av et legemiddel.
IL125645A IL125645A (en) 1996-02-06 1998-08-03 Use of a modified bacteriophage in the manufacture of a medicament
US09/927,420 US20020044922A1 (en) 1996-02-06 2001-08-10 Recombinant phages

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9600434A SE506771C2 (sv) 1996-02-06 1996-02-06 Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna

Publications (3)

Publication Number Publication Date
SE9600434D0 SE9600434D0 (sv) 1996-02-06
SE9600434L SE9600434L (sv) 1997-08-07
SE506771C2 true SE506771C2 (sv) 1998-02-09

Family

ID=20401289

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9600434A SE506771C2 (sv) 1996-02-06 1996-02-06 Fusionsprotein, bakteriofag uttryckande proteinet, dessas användning samt hybridoma celler och monoklonaler producerade av cellerna

Country Status (16)

Country Link
EP (1) EP0889955B1 (de)
JP (1) JP4015195B2 (de)
KR (1) KR100459638B1 (de)
CN (1) CN1125174C (de)
AT (1) ATE266091T1 (de)
AU (1) AU712767B2 (de)
CA (1) CA2244792A1 (de)
DE (1) DE69728975T2 (de)
ES (1) ES2221033T3 (de)
HU (1) HUP9901242A3 (de)
IL (2) IL125645A0 (de)
NO (1) NO323359B1 (de)
NZ (1) NZ331580A (de)
RU (1) RU2215032C2 (de)
SE (1) SE506771C2 (de)
WO (1) WO1997029185A1 (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000006717A2 (en) 1998-07-27 2000-02-10 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
GB9908195D0 (en) * 1999-04-09 1999-06-02 Microbiological Res Authority Treatment of intracellular infection
CA2376232A1 (en) 1999-06-14 2000-12-21 Genentech, Inc. A structured peptide scaffold for displaying turn libraries on phage
WO2002007742A2 (en) * 2000-07-25 2002-01-31 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Bacteriophage having multiple host range
US6914123B2 (en) 2001-04-17 2005-07-05 Genentech, Inc. Hairpin peptides with a novel structural motif and methods relating thereto
KR20040036176A (ko) * 2002-10-23 2004-04-30 (주)엘피스바이오텍 단백질의 특이적 결합을 매개로 한 박테리오파아지의선택적 숙주감염을 이용한 단백질간의 상호작용을분석하는 방법
CN102296051B (zh) * 2011-03-07 2014-09-17 江苏省农业科学院 一种宽宿主谱鸡白痢沙门氏菌噬菌体及其应用
RU2503716C1 (ru) * 2012-09-27 2014-01-10 Федеральное бюджетное учреждение науки Государственный научный центр прикладной микробиологии и биотехнологии (ФБУН ГНЦ ПМБ) ВИДОСПЕЦИФИЧЕСКИЙ ВИРУЛЕНТНЫЙ ШТАММ БАКТЕРИОФАГА, ОБЛАДАЮЩИЙ ЛИТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ Staphylococcus aureus, ВКЛЮЧАЯ МУЛЬТИРЕЗИСТЕНТНЫЕ ШТАММЫ
GB201308745D0 (en) * 2013-05-15 2013-06-26 Imp Innovations Bacteriophage
CN106198523A (zh) * 2016-07-06 2016-12-07 哈尔滨贝贝凯尔科技发展有限公司 微量元素检测试纸及其制备方法
AU2018344859A1 (en) 2017-10-04 2020-04-30 Hesperix SA Articles and methods directed to personalized therapy of cancer
US11939592B2 (en) * 2018-12-27 2024-03-26 National University Corporation Tokai National Higher Education And Research System Host bacterium specific nanoparticle
CN109679981A (zh) * 2019-02-21 2019-04-26 武汉大学 一种甲酰基肽定向进化噬菌体及其制备方法与应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9015198D0 (en) * 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5478731A (en) * 1991-04-12 1995-12-26 Stratagene Polycos vectors
SE9304060D0 (sv) * 1993-12-06 1993-12-06 Bioinvent Int Ab Sätt att selektera specifika bakteriofager

Also Published As

Publication number Publication date
JP2000505648A (ja) 2000-05-16
NO983456D0 (no) 1998-07-27
ES2221033T3 (es) 2004-12-16
NZ331580A (en) 1999-09-29
DE69728975T2 (de) 2005-05-04
JP4015195B2 (ja) 2007-11-28
DE69728975D1 (de) 2004-06-09
EP0889955A1 (de) 1999-01-13
HUP9901242A2 (hu) 1999-07-28
KR19990082041A (ko) 1999-11-15
ATE266091T1 (de) 2004-05-15
CN1210558A (zh) 1999-03-10
SE9600434D0 (sv) 1996-02-06
SE9600434L (sv) 1997-08-07
CA2244792A1 (en) 1997-08-14
NO323359B1 (no) 2007-04-10
HUP9901242A3 (en) 2000-03-28
IL125645A0 (en) 1999-04-11
NO983456L (no) 1998-10-06
IL125645A (en) 2006-08-20
WO1997029185A1 (en) 1997-08-14
CN1125174C (zh) 2003-10-22
RU2215032C2 (ru) 2003-10-27
EP0889955B1 (de) 2004-05-06
AU712767B2 (en) 1999-11-18
AU1681797A (en) 1997-08-28
KR100459638B1 (ko) 2005-02-24

Similar Documents

Publication Publication Date Title
Goodridge Designing phage therapeutics
Cao et al. Helicobacter pylori-antigen-binding fragments expressed on the filamentous M13 phage prevent bacterial growth
Kim et al. Characterization of a T5-like coliphage, SPC35, and differential development of resistance to SPC35 in Salmonella enterica serovar Typhimurium and Escherichia coli
EP0889955B1 (de) Rekombinante phagen
Bao et al. Morphologic and genomic characterization of a broad host range Salmonella enterica serovar Pullorum lytic phage vB_SPuM_SP116
CN111848789A (zh) 抗sars-cov-2病毒s蛋白的单链抗体及其用途
JP3574135B2 (ja) 特異的バクテリオファージの選択方法
US20020044922A1 (en) Recombinant phages
AU661465B2 (en) Pseudomonas peptide composition and method for producing the same
US6497874B1 (en) Recombinant phages
Ojobor The Noncontractile Phage Tail-Like Bacterial Killing Nanomachines–Characterizing the Specificity Determinants of the F-Pyocins of Pseudomonas aeruginosa
AU5328599A (en) Gastrointestinal bacterial antibody factories
CN118344443B (zh) 一种增强噬菌体对肠黏膜黏附能力的蛋白a
CN105294840B (zh) 一种用于预防和治疗肠致病大肠杆菌感染的肽段
Scherer Structural Analysis of Pseudomonas Phage Dev Virion-Associated RNA Polymerase (GP71)
Uddin et al. Associations between Bacteriophage Resistance and Antibiotic Resistance Phenotypes in Laboratory and Clinical strains of Salmonella Typhimurium
Emara et al. Expression of an anti-Pseudomonas aeruginosa lipopolysaccharide core recombinant antibody in Escherichia coli
CN118480121A (zh) 一种特异性结合金黄色葡萄球菌蛋白a的抗体及其应用
CN114921438A (zh) 假结核耶尔森氏菌效应蛋白及其应用
Jamalludeen Phages against porcine post-weaning diarrhea due to O149 Escherichia coli
Ranger The localizaton of a putative target cell binding domain of the pasteurella haemolytica A1 leukotoxin using a neutralizing single chain fragment variable
Kaluzny Investigation of the Wzy alpha and beta O-antigen polymerases in Pseudomonas aeruginosa
Lam The Role of Campylobacter jejuni in Guillain-Barré Syndrome
Çakan Evidence for a Novel Bacteriophage from Moraxella Catarrhalis
Narasanna et al. Experimental protection of ESBL producing Salmonella typhi bacteremic induced mice model by φGRCST; a therapeutic approach

Legal Events

Date Code Title Description
NUG Patent has lapsed